Evaluating the Use of Biosimilars for Rheumatologic Conditions
  • Program Overview
    Evaluating the Use of Biosimilars for Rheumatologic Conditions
    This program, featuring on-demand audio from an expert-led Webinar, downloadable slides, and 2 ClinicalThought commentaries, explores the regulatory approval pathways for biosimilars used in rheumatologic conditions as well as how they differ from their reference biologics and small molecule generics and their place in therapy.
  • Featured content
    In this downloadable slideset, William F. C. Rigby, MD, and Beth L. Jonas, MD, review key data to enhance your understanding of biosimilars and their clinical application to rheumatologic conditions.
    Date Posted: 7/18/2017
  • What should you tell your rheumatology patients about biosimilars?
    Date Posted: 7/18/2017
  • 1
  • 2
  • 3

Latest Content

4 of 4 Shown
4 of 4 Shown
Show 0 More
Loading...